Hans Biomed Corp · KRX:042520
Hans Biomed — Investor Presentation (November 2021)
26 slides from Hans Biomed's investor presentation, Nov 11, 2021
Slide 1: 공식 IR 자료
한스바이오메드 공식 IR 자료 2017 By 황덕구 과장 KOSDAQ, 042520
Slide 2: Product Portfolio, Infrastructure, Corporate governance
7|S742 1. Product Portfolio 2. Infrastructure 3. Corporate governance
Slide 3: History
7| B72 History 1999 - 2016 1993 $ BIAHPO| Soe AE) 1999 @ 1st U5 O|AIAH in Asia 2000 @ Ca ats se 2003 @ 1st 4}24 in Korea 1st Ht O|AYAH in Korea 2008 @ Fees cSel 2006 @ KOSDAQ AZ 042520) 2009 @ Ole#el 82 2012 @ 1st AATB S272 in Asa 2014 © 1st SHHAAIDYS 4 in Korea 2015 @ sadaae 1st SFE SAS in Korea 20
Slide 4: Product Portfolio
Product Portfolio Human Tissue Cosmeceutical tg 2 Images \ \ e oaey uuE who Bobo ee sche, ONSAFSEEHESE SANE ares NRHN GHelmiae Ne Demi Ises emia ys SEE ates gy Derma Slton SABLE Sea Aeionyaiviaoy T= UABYSMOInHOLAEHE! LoHAy Description oe See POLAR ae ARBELE SHE)-O10 [21 AI p FOL USE AMOS —-ARaReUeL
Slide 5: Infrastructure
Infrastructure BANE, 28S #4: 201714 PE: 1F New Technology R&D 1~3F MINT #2! 4F Broadcasting, Workshop 8F GMP Faailty (dinical) OF Cellular treatment R&D slAHO} Bt We, RST AE: 20198 R&D: Stem Cel Derived Exosome/ Medium 722: cGMP Facility 's09001/1S014001/ 1so22716 Za BAe, HST MB: 20244 (GS 201341) a
Slide 6: Corporate governance
7| S72 Corporate governance lA AE: 199914 enjcey | SSI 23108 “ole (48:05 C209 SB: 20154 ase e278 H| Glo An oe SB: 200 2alel +298 2: 20144 AB: 20184 aaa e318 a Ala =: 168 Hans USA #2: 201 BAe 248 Az: 20154 aaa S28 #1 201814 aaa e148 AB: 201914 2Alal +:88 2) 20194 Ale 68 #2: 20194 ale =:78 Hans Columb
Slide 7: ABMe
ABMe Silicone Polymer Medical Device Biologics Cosmeceutical
Slide 8: Botox and filler market growth
보톡스 CAGR 8% (십억달러) 필러 CAGR 11% 7 6.5 6 6 5.5 5.1 5 4.4 4.7 4.2 4.5 3.9 4 4 3.5 3.5 3.2 2.9 3 3 2.6 2.5 2 2 1.5 1 1 0.5 0 0 2018 2019(E) 2020(E) 2021(E) 2022(E) 2023(E) <출처 : Ipsen 'Investor Day 2019' Daedal Research, Global Botulinum Toxin Market 2018 2019 2018 vs 2018 2015 vs 2015 보톡스 627만 609만 3%
Slide 9: (십억원) 25.0 20.0 5.0 15.0 1.3 11.7 10.0 7.7 2.6 1.2 3.8 4.7 2.5
(십억원) 25.0 20 20.0 5.0 15.0 1.3 11.7 10.0 7.7 2.6 1.2 3.8 4.7 2.5 13.7 5.0 1.3 1.7 7.9 1.4 3.9 .0 1.6 2016 2017 2018 2019 2020 (십억원) 16.0 13.7 14.0 12.0 1.4 10.0 1.5 8.0 7.9 4.2 6.0 3.9 2.0 4.0 1.6 1.8 2.0 0.8 .5 4.9 1.8 2.3 .0 2016 2017 2018 2019 2020
Slide 10: Approved / Registered Easy&Fine
2016 2021 제품 2개 11개 (43&17) (43&17&Easy&Fine&Ko&Mono) 적용증 1개 4개 (Lifting) (Lifting&Nose&Fix&Regenerate) 43&17 Easy&Fine Mono Series Approved / Registred 25/28 22/32 12/25 2021.2Q~2022.4Q 2023.1Q~2025.4Q 2026.1Q ~
Slide 11: (십억원) 4.5 2.9 15.6 17.7 17.6 16 2017 (십억원) 25.0 20.0 1.7 1.7 2.8
(십억원) 30 25 4.5 20 3 2.9 3 15 10 20 21 15.6 17.7 17.6 5 0 2016 2017 2018 2019 2020 (십억원) 25.0 20.0 1.7 1.7 2.8 1.7 1.5 3.1 1.5 15.0 1.5 2.6 2.1 3.1 5.9 10.0 5.7 6.3 7.6 4.3 5.0 8.7 6.7 7.6 7.6 7.5 .0 2016 2017 2018 2019 2020
Slide 12: RCR surgery volume
(천명) 80.0 74.8 75.0 69.5 70.0 66.0 65.0 60.0 2018 2019 2020 RCR 수술 건수 <출처 : 보건의료빅테이터 개방시스템 : 연 7월부터 다음해 6월 기준 <출처 : 한스케어 내부 조사자료 2021 (십억원) 5 4 3 4.7 2 3.6 2.7 1 1.9 0.8 1.3 0 2020 2021E 2022E 2023E 2024E 2025E
Slide 13: Breast cancer incidence
(천명) (명) 30.0 25.9 4500 3888 4000 3631 25.0 21.5 19.4 3500 20.0 16.8 14.7 21.8 3000 2781 15.0 12.1 18.4 10.1 16.7 2500 8.8 14.6 10.0 6.4 12.8 2000 10.9 3.1 4.0 5.0 8.2 9.2 1.9 2.2 2.7 1500 .4 .5 .9 1.2 812 910 1279 6.0 1000 626 738 536 .0 380 2000 2002 2004 2006 2008 2010 2012 2014 2016 500 99 0 Inv
Slide 14: 800,000 619,774 600,000 493,876 368,924 167 400,000 148 221,147 220,260 150 200,000 77 88
800,000 300 259 619,774 250 220 600,000 493,876 368,924 200 167 400,000 148 221,147 220,260 150 200,000 77 88 100 68 66 59 43 0 50 21 18 2016 2017 2018 2019 2020 1 2 3 4 5 6 7 8 9 10 11 12
Slide 15: What is an exosome?
엑소좀 (Exosome) 이란? (십억원) 세포에서 분비되는 지질이중막 소포체임. 8 7 생체 내 세포 간의 정보전달 역할 6 다른 세포와 조직의 기능적, 생리적 변화 유도 5 2010년 이후 질환 치료와 화장품, 건강식품까지 4 3 6.6 6.8 활용 범위 확대 2 4.1 3.2 1 0.9 0 2016 2017 2018 2019 2020 중간엽줄기세포 신경줄기세포 (Mesenchymal Stem Cell) (Neural Stem Cell) 엑소좀 피부세포 증식 효능 엑소좀 전자 현미경 사진 (TEM) 엑소좀을 이
Slide 16: Hans Pharma exosome technology platform
한스파마 엑소좀 기술 Platform 사업화 계획 1. 줄기세포 대량생산 GMP 적용 bioreactor platform • 엑소좀 기능성 화장품 제형 및 GMP 생상 공정 완료 (21년 4Q) • 엑소좀 화장품 원료 안전성 자료 확보 (22년 1Q) - 줄기세포 대량 생산 system 확보 • 엑소좀 기능성 화장품 출시 - 화장품 원료 줄기세포 배양액 대량 생산 system 확보 (22년 2Q, 피부 재생/주름개선, 23년 1Q 탈모 완화) (관련 기능성 화장품 제품 금년도 하반기 출시 예정) - 활성 및 QC 검증 기술 및 배양
Slide 17: (십억억) 30.0 25.0 2.4 20.0 2.3 15.0 2.6 24.2 10.0 19.9 1.8 5.0 1.1
(십억억) 30.0 25.0 2.4 20.0 2.3 15.0 2.6 24.2 10.0 19.9 1.8 5.0 1.1 10.9 6.7 3.9 .0 2016 2017 2018 2019 2020 (십억원) 30.0 25.0 24.2 19.9 3.1 20.0 15.0 2.5 10.9 10.0 6.7 19.3 3.9 2.4 15.0 5.0 3.4 6.7 .0 1.5 2016 2017 2018 2019 2020
Slide 18: Profit & Loss BD
Profit & Loss BD Geographic BD SG&A BD Quarter Result
Slide 19: Sales, gross profit and operating profit
(십억원) 45.0 42.5 70% 40.1 (십억원) 40.0 60% 90.0 35.0 27.3 50% 30.0 80.1 25.0 40% 80.0 2.3 20.0 18.3 30% 4.1 15.0 13.4 70.0 67 4.5 20% 10.0 5.0 10% 6.8 60.0 0.0 0% 21.0 3.0 2016 2017 2018 2019 2020 51.7 50.0 매출총이익 매출총이익률 6.6 20.0 39.1 3.0 40.0 20.0 3.2 0.9 29 2.9 17.6 30.0 11.7 (십억원) 2.5 17.7 14.0 30% 1
Slide 20: Threads, Breast/Skin, Bone, Other
8 80 7 70 6 60 5 50 4 40 3 30 2 20 1 10 0 0 2017 2018 2019 2020 2017 2018 2019 2020 Threads Breast/Skin Bone (Biologics) Other (Facial/Hair/Scar) Threads Breast/Skin Bone (Biologics) Other (Facial/Hair/Scar)
Slide 21: Salaries, employees and R&D ratio
(명) (억) (억) 140 600 60 7% 8% 489 6% 7% 120 500 50 100 379 55 6% 400 40 5% 80 284 40 300 30 4% 60 201 2% 2% 3% 145 200 20 40 1% 2% 10 20 100 2 11 1% 8 0 0% 0 0 2016 2017 2018 2019 2020 2016 2017 2018 2019 2020 Salaries Employees R&D Ratio (억) (억) 70 7% 8% 60 7% 7% 8% 60 7% 6% 6% 6% 50 50 59 6% 6% 5%
Slide 22: Annual and quarterly results
(십억원) 30.0 24.5 (십억원) 25.0 90.0 40% 20.0 19.0 18.9 18.4 17.8 17.8 80.1 16.8 16.7 15.7 80.0 14.7 14.5 35% 15.0 12.1 70.0 67.0 9.8 10.1 9.6 10.5 10.0 30% 60.0 5.0 51.7 25% 50.0 .0 39.1 17-1Q 17-2Q 17-3Q 17-4Q 18-1Q 18-2Q 18-3Q 18-4Q 19-1Q 19-2Q 19-3Q 19-4Q 20-1Q 20-2Q 20-3Q 20-4Q 40.0 20% 29.0 30.0 15
Slide 23: R&D Pipelines
APMICH IZ 1S el 1. R&D Pipelines 2. Embolic Material 3. Cartilage Treatment
Slide 24: R&D Embolic Material
R&D Embolic Material 100% Holl AZ, SA] Sol] At sy atals! BEE M - Sic} Molo) Cro) Aet aparsiol 19) gzaet > 201949 IHS BSA ya 2022.2Q ASA Alat LRG SiDtiy X= BEYO! ANAIZO| OLA AS StrH AH > 2021.3Q HH ALSFAY S{7} AS > 2024.1Q SLY ALFA] S{7} ALAY > RE > 2024.20 SLY AFA BHOHSH7} Ste ABS Ases, SBAF, ISHS,
Slide 25: R&D Cartilage treatment
R&D Cartilage treatment — SUst AZ *| HAI, 2021 2Q IND AS AAMYS BASS} AS Ho|AS 37 |MES MAE! PALAIA SUS ClSet Lf Ane v HOLL AAI BO v2 OA] OFM EyofotBal if A-paste™ 7c a AEZLY AWS aaa AAR SIBHE Offthe-shelf MSS & 42/5491 Als Abs HANS Berg aA ss aHSMSABAE B/Se Se Be A-paste-C TAP-C Ay : A a A vy Chat Bt
Slide 26: A-Paste-C Target Market
A-Paste-C Target Market 제품설명 및 특장점 글로벌 골관절염 환자 중 무릎골관절염 (K&L Grade 2이상) 환자 예측 • 적응증 : 연골결손의 치료 단위 : 천명 300,000 5.64% 0.58% 11.05 • 제품성분 : 연골전구세포 및 세포외기질 성분으로 구성 % 8.43% • 제품특징 : 접착성이 강한 젤 타입의 조직재생 치료제 250,000 • 특장점 200,000 12.45 - 무릎연골조직(초자연골)과 유사한 특성을 보유 % 150,000 - 생체 내 연골조직과 우수한 융합력 보유 - 환자의 결손부위